The Reverse Vaccinology 2.0 technique will allow isolation of human monoclonal antibodies from convalescent patients, to develop both a cure and a future vaccine.   Rome/Siena, 26th March 2020 –  In these days of global emergency due to the spread of COVID-19, the vAMRes Lab at Toscana Life Sciences (TLS) Foundation (based in Siena, Italy) has started a research project for the development of human monoclonal antibodies against coronavirus SARS-CoV-2, with the aim of using them for prophylactic/therapeutic purposes and as molecular baits for the discovery of vaccine antigens. The project is conducted in collaboration with the Spallanzani INMI (National Institute of Infectious Diseases) Hospital, based in Rome, with which the Foundation recently signed a two-year agreement for the development of human monoclonal antibodies that can offer a rapid response to emerging infectious diseases. In particular, Spallanzani INMI contributes the renowned expertise in infectious diseases, the possibility to access clinical data from patients with COVID-19 and the ability to isolate, cultivate and characterize the pathogen. “Since the first weeks of the epidemic, the Spallanzani Hospital has been at the forefront of the fight against COVID-19 – states the scientific director of the Institute, Giuseppe Ippolito – Our virology laboratory was among the first….

L’articolo COVID-19: in Italy, Toscana Life Sciences Foundation and Spallanzani Hospital sign agreement for innovative research project. proviene da Toscana Life Sciences.

Source: Toscana Life Sciences

Utilizzando il sito, accetti l'utilizzo dei cookie da parte nostra. maggiori informazioni

Questo sito utilizza i cookie per fornire la migliore esperienza di navigazione possibile. Continuando a utilizzare questo sito senza modificare le impostazioni dei cookie o cliccando su "Accetta" permetti il loro utilizzo.